

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Xsira Pharmaceuticals, Inc.	FORMERLY Norak Biosciences, Inc.	03/09/2005	a Delaware corporation:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Molecular Devices Corporation		
<b>Street Address:</b>	1311 Orleans Drive		
<b>City:</b>	Sunnyvale		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94089		
<b>Entity Type:</b>	a Delaware corporation:		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
Registration Number:	2672722	TRANSFLUOR	
Serial Number:	78356488	LITE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(703)836-2021		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	(703)836-6620		
<b>Email:</b>	bnitrademark@burnsdoane.com		
<b>Correspondent Name:</b>	Bassam N. Ibrahim		
<b>Address Line 1:</b>	P.O. Box 1404		
<b>Address Line 4:</b>	Alexandria, VIRGINIA 22313-1404		
<b>NAME OF SUBMITTER:</b>	Bassam N. Ibrahim		
<b>Signature:</b>	/bassam n. ibrahim/		
<b>Date:</b>	04/08/2005		

CH \$65.00 2672722

Total Attachments: 3

source=033072-105 assignment\_#page1.tif

source=033072-105 assignment\_#page2.tif

source=033072-105 assignment\_#page3.tif

## TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT (the "*Agreement*") is made and effective as of March 9, 2005, by and between Xsira Pharmaceuticals, Inc. (formerly Norak Biosciences, Inc.), a Delaware corporation having an address at 7030 Kit Creek Road, Morrisville, North Carolina 27560 ("*Seller*"), and Molecular Devices Corporation, a Delaware corporation, having its principal place of business at 1311 Orleans Drive, Sunnyvale, California 94089 ("*Purchaser*").

**WHEREAS**, Seller has adopted, owns, uses or intends to use the registered and unregistered trademarks set forth in Attachment 1 of this Agreement (collectively, the "*Marks*");

**WHEREAS**, Seller has obtained registrations for or has applied to register certain of the Marks as set forth in Attachment 1 of this Agreement (the "*Applications and Registrations*");

**WHEREAS**, Purchaser desires to acquire all of Seller's right, title and interest in and to the Marks and the Applications and Registrations and the portion of Seller's business to which the Marks pertain pursuant to the Asset Purchase Agreement by and between Seller and Purchaser dated as of the date hereof (the "*Asset Purchase Agreement*").

**NOW, THEREFORE**, for good and valuable consideration, the receipt of which is hereby acknowledged:

1. Seller hereby sells, assigns and transfers to Purchaser, its successors and assigns, as the successor to Seller's business to which the Marks pertain, all its right, title and interest in and to the Marks and Applications and Registrations, including all common law rights, in the United States of America and all other countries and jurisdictions of the world, together with the goodwill of the business symbolized by the Marks and Applications.

2. Seller hereby assigns to Purchaser all causes of action, claims and rights to damages or profits, due or accrued, arising out of past infringement of the Marks, or injury to the goodwill associated with the Marks, as well as the rights to sue for and recover the Marks in Purchaser's own name.

3. Seller covenants that it will cooperate in any actions (i) necessary or useful for Purchaser to effectuate the transfer and assignment of the Marks to Purchaser, including the execution of documents necessary to record the assignment with the appropriate government agencies, at Seller's expense; (ii) necessary or useful for Purchaser to prosecute, renew or register its rights, title and interests in and to the Marks and Applications, including United States and foreign registrations, at Purchaser's expense, and (iii) brought to enforce the rights accompanying this Assignment against third parties, at Purchaser's expense.


4. In the event of any conflict between this Agreement and the Asset Purchase Agreement, the Asset Purchase Agreement shall control. Nothing in this Agreement shall be deemed to amend or modify in any way any of the terms and conditions of the Asset Purchase Agreement or any rights or obligations of the parties thereto.

**IN WITNESS WHEREOF**, Seller and Purchaser have each caused this Trademark Assignment Agreement to be duly executed and delivered as of the date first written above.

PURCHASER:

**MOLECULAR DEVICES CORPORATION**

By:

  
\_\_\_\_\_

Print Name: Tim Harkness

Title: Chief Financial Officer

SELLER:

**XSIRA PHARMACEUTICALS, INC.**

By:

  
\_\_\_\_\_

Print Name: ROGER D. BUCVINS

Title: CEO

*Signature Page for Trademark Assignment Agreement*

**ATTACHMENT 1**

<b>TRADEMARK</b>	<b>JURISDICTION</b>	<b>APPLICATION/ REGISTRATION NO.</b>
LITE	United States	78/356,488
TRANSFLUOR	United States	2672722
TRANSFLUOR	Canada	114172900
TRANSFLUOR	European Community	2723740
TRANSFLUOR	European Community	1953587
TRANSFLUOR	Japan	4676872
<b>COMMON LAW TRADEMARKS</b>		
DESENSITIZATION ACTIVE COMPOUND DAC NON-DESENSITIZING LIGAND NDL NON-DESENSITIZING AGONIST NDA		